NVO - Spark Newswire

1 minute read

Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation

Today, 9:26 PM

Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…

ABBV

2 minute read

Jimmy Kimmel Jokes At Oscars About Hollywood Stars Using This Diabetes Drug To Lose Weight — Roasts Will Smith Slap Too

By Aaron Bry

Today, 9:26 PM

During the 95th Academy Awards ceremony hosted by Jimmy Kimmel on Sunday night, he poked fun at the rumor that Hollywood actors are using Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, to lose weight.

NVO

1 minute read

Here’s How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years

By Benzinga Insights

Today, 9:26 PM

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 15.4% on an annualized basis…

NVO

1 minute read

Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race

By Vandana Singh

Today, 9:26 PM

Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…

GPCR

1 minute read

Novo Nordisk’s Partner Heartseed Has Dosed The First Patient In Phase 1/2 Study (LAPiS Study) With HS-001, An Investigational Cell Therapy For Heart Failure

By Benzinga Newsdesk

Today, 9:26 PM

An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure, and has given approval for the study to continue

NVO

1 minute read

Novo Nordisk Q4 EPS $0.81 Misses $0.85 Estimate, Sales $6.44B Miss $6.84B Estimate

By Benzinga Newsdesk

Today, 9:26 PM

Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.81 per share which missed the analyst consensus estimate of $0.85 by 4.71 percent. This is a 10.96 percent increase over earnings of $0.73 per share from the same

NVO

1 minute read

Analyst Views Novo Nordisk’s Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly’s Tirzepatide

By Vandana Singh

Today, 9:26 PM

Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.

AMGN

1 minute read

Jim Cramer Says Avoid This Stock: ‘Too Expensive’

By Priya Nigam

Today, 9:26 PM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Blackline, Inc. (NASDAQ: BL) was an enterprise software company that was losing money.

1 minute read

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says

By Vandana Singh

Today, 9:26 PM

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has…

AZN

1 minute read

Why Jim Cramer Can’t Recommend Investing In Carl Icahn’s Company

By Priya Nigam

Today, 9:26 PM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Koninklijke Philips NV (NYSE: PHG) is "just not a well-enough run company." He added Danaher Corporation (NYSE: DHR) is the

DHR

Feed Symbols: NVO